These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 31939441)
1. Correlations between maximum standardized uptake value measured via Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441 [TBL] [Abstract][Full Text] [Related]
2. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma]. Li J; Zhao M; Yuan L; Liu Y; Ma N Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):136-140. PubMed ID: 35123616 [TBL] [Abstract][Full Text] [Related]
4. Nomograms based on SUVmax of Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476 [TBL] [Abstract][Full Text] [Related]
5. [Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype]. Zhang J; Wang R; Fan Y; Fu Z; Zhang X; Liao X; Liu M; Kang L; Cui Y; Wang Y; Jiang Q Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(33):2576-9. PubMed ID: 25511487 [TBL] [Abstract][Full Text] [Related]
6. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma. Akkas BE; Vural GU Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371 [TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement. Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829 [TBL] [Abstract][Full Text] [Related]
8. Prognostic role of baseline Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563 [TBL] [Abstract][Full Text] [Related]
9. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma. Li XF; Fu Q; Dong YW; Liu JJ; Song XY; Dai D; Zuo C; Xu WG World J Gastroenterol; 2016 Sep; 22(34):7787-96. PubMed ID: 27678362 [TBL] [Abstract][Full Text] [Related]
10. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer. Mohamadien NRA; Sayed MHM Nucl Med Commun; 2021 Jun; 42(6):656-664. PubMed ID: 33560720 [TBL] [Abstract][Full Text] [Related]
11. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST]. Li SX; Tang MD; Lin DY; Liu DJ; Lyu QH; Zhang JP; Cai ZH Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):821-827. PubMed ID: 29151288 [No Abstract] [Full Text] [Related]
12. Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia. Nakachi S; Okada M; Morishima S; Agarie Y; Kitamura S; Uchibori S; Tomori S; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Morichika K; Nishi Y; Tomoyose T; Karube K; Fukushima T; Murayama S; Masuzaki H Hematology; 2017 Oct; 22(9):536-543. PubMed ID: 28397608 [TBL] [Abstract][Full Text] [Related]
13. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study. Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508 [TBL] [Abstract][Full Text] [Related]
14. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
15. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma. Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465 [TBL] [Abstract][Full Text] [Related]
16. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma. Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526 [TBL] [Abstract][Full Text] [Related]
17. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma. Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643 [TBL] [Abstract][Full Text] [Related]
19. The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer. Eryilmaz A; Cengiz A; Basal Y; Meteoglu I; Omurlu IK; Yurekli Y J Cancer Res Ther; 2018; 14(5):994-998. PubMed ID: 30197337 [TBL] [Abstract][Full Text] [Related]
20. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma]. Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]